Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Sonny Blue who wrote (809)	5/6/1998 6:58:00 PM
From: John Bloxom	Read Replies (1) \| Respond to of 2135

$18.00 at some point between now and 12/31/98. BTW, I have profound respect for Dr. Folkman's work and for ENMD's management. Regards, John

To: Sonny Blue who wrote (809)	5/6/1998 7:07:00 PM
From: Secret_Agent_Man	Read Replies (2) \| Respond to of 2135

14:14 ET Oxigene (OXGN) 18 3/8 +4 (+28%): British doctors said they expect to begin human trials of a new cancer drug that cuts off blood supply to tumors in six months, ahead of U.S. biotechs which are working on a similar approach, according to Reuters. Their wonder-drug, Combretastatin, was discovered by an Arizona State University professor and has been licensed to Oxigene. Volume 1 mln shares. Stock also trades warrants "OXGNW" (5 3/4 +2 3/8, +70%). EntreMed said it would be at least a year before its drug is ready for human trials.

To: Sonny Blue who wrote (809)	5/6/1998 9:14:00 PM
From: Jason Loren Bauer	Respond to of 2135

22 would be fine by me! still holding puts